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The current outburst of a new H1N1 swine 
influenza strain(s) in México and the United States is 
causing great concern in health authorities and in the 
general population [1]. With the World Health 
Organization (WHO) reporting the pandemic 
potential of the new strain, it is necessary to 
determine which therapeutic options are available 
until a specific vaccine is available. Based on 
information from the Centre for Disease Control 
(CDC), the virus is sensitive to oseltamivir and 
zanamivir. Antivirals are strongly affected by viral 
mutations; thus their efficiency could be lost as the 
virus changes.  
The cytokine hypothesis proposes that the host 
immune system and autoinflammation is the main 
cause underlying respiratory distress in severe cases 
of influenza. The “cytokine storm” is a consequence 
of disregulated immune responses to the virus [2]. 
Influenza virus employs human signaling pathways 
to replicate, interfering with normal cell physiology 
and leading to undesired effects such as 
overinduction of cytokines and chemokines. Host 
intracellular signaling pathways or host immune 
mediators, blocked by immunomodulatory drugs, are 
not affected by viral mutations and therefore may be 
suitable targets for treating severe influenza patients. 
A wide range of immunomodulatory drugs have been 
proposed for influenza treatment, but there is limited 
experience in their use in this context [3,4]. 
Macrolides are molecules with antibacterial 
activity that also have remarkably anti-inflammatory 
properties. Macrolides exert both stimulatory and 
inhibitory effects on leukocytes. These effects seem 
to be related to the activation state of the leukocytes, 
facilitating bacterial killing as well as resolving local 
inflammation [5].  The benefits of macrolides for 
treatment of community-acquired pneumonia appear 
to be mediated by both anti-bacterial and non-
antibacterial properties [6]. Recent research of the 
immunomodulatory properties of azithromycin 
implies that azithromycin may have a previously 
unknown short-term biphasic modulatory effect on 
inflammation. It enhances host defence mechanisms 
shortly after initial administration followed by 
inhibition of local infection/inflammation at a later 
period [7]. Sato et al. demonstrated that 
administration of erythromycin at a dose of 3.3 
mg/kg/d (intraperitoneally, from Days 1 to 6 after 
infection), significantly improved the survival rate of 
mice infected with a H2N2 influenza virus [6]. 
Erythromycin significantly decreased interferon 
gamma (IFNg) in infected lungs and decreased the 
number of inflammatory cells recovered in lung 
lavage fluid 6 d after virus infection. The treatment 
also resulted in a dose-dependent decrease in the 
level of nitrite/nitrate (metabolites of nitric oxide, 
NO) in the serum and the NO synthase (NOS)-
activity in the lungs of the virus-infected mice.  
Tsurita et al. showed an early augmentation of 
interleukin (IL)-12 levels in the airway of mice 
administered orally with clarithromycin, resulting in 
alleviation of influenza infection [8]. 
Clarithromycin has been successfully used in a 
clinical study in respiratory syncytial virus 
bronchiolitis in children [9]. Treatment with 
clarithromycin was associated with a statistically 
significant reduction in the length of hospital stay, the 
duration of need for supplemental oxygen, and the 
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need for beta2-agonist treatment. There were 
significant decreases in plasma IL-4, IL-8 and 
eotaxin levels after three weeks of treatment with 
clarithromycin. Readmission to the hospital within 
six months after discharge was significantly lower in 
the clarithromycin group. 
Ninomiya reported beneficial effects of 
macrolides on the resolution of symptoms, duration 
of illness and complications in children with 
pneumonia and influenza [10]. 
Inmunomodulation by using steroids was 
extensively employed during the SARS Coronavirus 
outburst in 2003, with controversial results. 
Treatment with corticoids translated into some 
beneficial effects in most of the studies reported, but 
maintained doses of steroids could lead to bacterial 
infection and sepsis [11]. Macrolides could be safely 
employed for immunomodulatory purposes since 
these drugs do not pan-immune-suppress. 
Furthermore, it could be used to prevent secondary 
infections by bacteria in those patients severely 
affected by the novel H1N1 viruses, such as 
A/California 04/09 and similar strains. Leelarasamee 
et al. reported a case of rapidly progressing H1N1 
influenza improving with a combination of 
oseltamivir and clarithromycin [12].  
Clarithromycin inhibits the middle to late stage 
of the influenza virus replication cycle, resulting in 
inhibition of progeny virus production from the 
infected cells [13]. Macrolides could mediate this 
effect by inhibiting intracellular hemagglutinin HA0 
proteolisis [14]. The inhibitory effects on influenza 
virus replication of macrolides has been known since 
the 80s [15] and have been observed for other viruses 
such as Sindibis virus [16]. Other drugs such as 
statins and Pentoxifylline might have beneficial 
effects in the treatment of severe influenza, but there 
is much less information available on their efficiency 
profiles in the treatment of influenza infection 
[17,18]. 
We propose here to utilize macrolides in the 
treatment of severe disease caused by the novel 
H1N1 swine flu reassortment influenza viruses now 
circulating in Mexico, the United States, Canada and 
other countries. We propose macrolides be used in 
combination with antivirals, in order to diminish the 
systemic inflammatory response leading to 
pneumonia and fatal outcome.  
Macrolides are easily accessible: they are used in 
the hospitals of both developed and developing 
countries to treat bacterial infection; they are 
relatively cheap; and they show a good toxicity 
profile. Administration could be employed on the 
basis of a clinical score including high fever, chest X-
Ray images and O2 saturation as predictors for 
disease outcome. 
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